Copertina

Treating asymptomatic follicular lymphoma: What is the score?

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ghassan Zammar, Chan Y. Cheah
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	British Journal of Haematology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

T‐cell/histiocyte‐rich large B‐cell lymphoma in the era of novel immunotherapy: A focused review
di: Joleen P. Choy, et al.
Pubblicazione: (2025)

Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma
di: Xuelei Li, et al.
Pubblicazione: (2024)

Real‐world experience with CAR‐T therapy in relapsed and refractory follicular lymphoma
di: Nicolás Triantafilo, et al.
Pubblicazione: (2025)

Response to ‘Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma’
di: Ángel Serna, et al.
Pubblicazione: (2026)

18 F ‐ FDG PET / CT impact in grade 3B follicular lymphoma
di: Domenico Albano
Pubblicazione: (2024)

Single gene mutations and prognosis in limited‐stage follicular lymphoma treated with radiation therapy
di: Samantha A. Hershenfeld, et al.
Pubblicazione: (2024)

Transformation and causes of death in follicular lymphoma: A Finnish nationwide population‐based study
di: Ilja Kalashnikov, et al.
Pubblicazione: (2025)

The value of semiquantitative PET features and end‐of‐therapy PET in grade 3B follicular lymphoma
di: Allison Barraclough, et al.
Pubblicazione: (2024)

Limited diagnostic utility of bone marrow sampling in PET ‐defined limited‐stage follicular lymphoma
di: Marissa Solow, et al.
Pubblicazione: (2026)

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second‐line setting
di: Ángel Serna, et al.
Pubblicazione: (2026)

Two‐year follow‐up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study
di: Yuqin Song, et al.
Pubblicazione: (2025)

CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
di: Emil Arjun Kumar, et al.
Pubblicazione: (2024)

An international real‐world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators
di: Catherine Tang, et al.
Pubblicazione: (2025)

Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study
di: Swetha Kambhampati Thiruvengadam, et al.
Pubblicazione: (2025)

Exposure to obinutuzumab does not affect outcomes of SARS ‐ CoV ‐2 infection in vaccinated patients with newly diagnosed advanced‐stage follicular lymphoma
di: A. Pinto, et al.
Pubblicazione: (2024)

Progression‐free survival is a weakly predictive surrogate end‐point for overall survival in follicular lymphoma: A systematic review and meta‐analysis
di: Charles J. Milrod, et al.
Pubblicazione: (2024)

Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open‐label study ( ACE ‐ LY ‐003)
di: Paolo Strati, et al.
Pubblicazione: (2024)

A low lymphocyte‐to‐monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis
di: Pablo Mozas, et al.
Pubblicazione: (2025)

Duration of anti‐CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2‐year maintenance paradigm
di: Michal Nordkin, et al.
Pubblicazione: (2025)

Checkpoint inhibitors, obinutuzumab plus PET ‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘ FLUORO’ study
di: Arina Martynchyk, et al.
Pubblicazione: (2026)

EBV‐positive inflammatory follicular dendritic cell sarcoma, an entity by many names
di: Xin Zhou, et al.
Pubblicazione: (2024)

Clonal haematopoiesis: A common progenitor for cytotoxic peripheral T‐cell lymphoma and angioimmunoblastic T‐cell lymphoma
di: Antonio Vogelsberg, et al.
Pubblicazione: (2024)

The importance of assessing the fitness of older patients with newly diagnosed diffuse large B‐cell lymphoma and classic Hodgkin lymphoma
di: Vittorio Ruggero Zilioli, et al.
Pubblicazione: (2025)

Management of vaccinations in patients with non‐Hodgkin lymphoma
di: Michele Merli, et al.
Pubblicazione: (2024)

Paradoxical role and therapeutic potential of autophagy in lymphomas
di: Qian‐Qian Yu, et al.
Pubblicazione: (2025)

We are on the right track for mantle cell lymphoma
di: Alessia Moioli, et al.
Pubblicazione: (2025)

Peripheral T‐cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK‐negative
di: Karthik A. Ganapathi, et al.
Pubblicazione: (2024)

Large cell lymphoma through a liquid lens
di: Jake Shortt, et al.
Pubblicazione: (2024)

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T‐cell lymphomas
di: Christina Poh, et al.
Pubblicazione: (2026)

T‐cell lymphoblastic lymphoma in children, adolescents and young adults
di: Marcel te Vrugt, et al.
Pubblicazione: (2025)

Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells
di: Radu Chiriac, et al.
Pubblicazione: (2025)

An atypical bilobed and binucleated splenic marginal zone lymphoma
di: Quentin Amiot, et al.
Pubblicazione: (2026)

Arborising telangiectasia in intravascular large B‐cell lymphoma
di: Zhu Huiying, et al.
Pubblicazione: (2025)

External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the Brazilian Hodgkin lymphoma registry
di: Valeria Buccheri, et al.
Pubblicazione: (2024)

Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population‐based study
di: Trine Trab, et al.
Pubblicazione: (2025)

Intravascular large B‐cell lymphoma presenting with haemophagocytic syndrome
di: Pedro Baptista, et al.
Pubblicazione: (2024)

Lymphocyte dynamics after CAR ‐T therapy for non‐Hodgkin lymphoma
di: Sarah Dingli, et al.
Pubblicazione: (2026)

Aberrant antioxidant responses in B‐cell non‐Hodgkin lymphoma
di: Nicolas Vallet, et al.
Pubblicazione: (2025)

Peripheral blood involvement in extra‐nodal marginal zone lymphoma
di: Izidore S. Lossos, et al.
Pubblicazione: (2025)

New standards of care for treatment of diffuse large B‐cell lymphoma
di: Chathuri Abeyakoon, et al.
Pubblicazione: (2024)